Neogenomics (NEO) Cash from Financing Activities (2010 - 2026)

Neogenomics has reported Cash from Financing Activities for 17 years, with the latest figure at -$338000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 135.62% year-over-year to -$338000.0; the trailing twelve-month figure through Mar 2026 stood at -$201.6 million (down 4317.93% YoY), and the FY2025 full-year result was -$200.3 million, down 4410.98% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$338000.0, down from $431000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $6.1 million in Q1 2022, with the low at -$202.4 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged -$10.6 million across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 2971.88% — and 2025, when it sank 10396.69%.
• Neogenomics' Cash from Financing Activities stood at $1.8 million in 2022, then declined by 29.52% to $1.3 million in 2023, then plunged by 45.91% to $687000.0 in 2024, then plunged by 37.26% to $431000.0 in 2025, then tumbled by 178.42% to -$338000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$338000.0 (Q1 2026), $431000.0 (Q4 2025), and $765000.0 (Q3 2025), per Business Quant data.